Real-world effectiveness of adalimumab in patients with moderate-to-severe hidradenitis suppurativa: the 1-year SOLACE study.
W GulliverA AlaviM C WisemanM J GooderhamJ RaoM S AlamKim A PappO DesjardinsC JeanPublished in: Journal of the European Academy of Dermatology and Venereology : JEADV (2021)
The effectiveness of adalimumab was maintained during this 1-year period, and an optimal gain was documented for patients with medium and high AN counts. These real-world data support a prompt treatment of HS patients and the use of IHS4 to monitor treatment.
Keyphrases
- hidradenitis suppurativa
- randomized controlled trial
- end stage renal disease
- rheumatoid arthritis
- systematic review
- newly diagnosed
- ejection fraction
- chronic kidney disease
- prognostic factors
- peritoneal dialysis
- combination therapy
- machine learning
- systemic lupus erythematosus
- big data
- patient reported outcomes
- smoking cessation